Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2021-06-30, filed 2021-08-16, with 30 holding rows worth $476,717,000.

Accession
0001172661-21-001868
Filed
2021-08-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2021

A holdings report, 30 entries on the cover page, a total value of $476,717,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $476,717,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MACROGENICS INC556099109COM1,378,495$37,026,000thousands by filing date
ROCKET PHARMACEUTICALS INC77313F106COM817,040$36,187,000thousands by filing date
ARENA PHARMACEUTICALS INC040047607COM NEW505,670$34,487,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock176,406$31,649,000thousands by filing date
INSULET CORP COM45784P101Stock104,600$28,714,000thousands by filing date
EXELIXIS INC COM30161Q104Stock1,394,107$25,401,000thousands by filing date
COLLEGIUM PHARMACEUTICAL INC19459J104COM861,410$20,364,000thousands by filing date
KADMON HLDGS INC48283N106COM4,830,000$18,692,000thousands by filing date
INTELLIA THERAPEUTICS INC45826J105COM100,000$16,191,000thousands by filing datecall
MIRATI THERAPEUTICS INC60468T105COM100,000$16,153,000thousands by filing date
TRAVERE THERAPEUTICS INC89422G107COM1,084,300$15,820,000thousands by filing date
AMICUS THERAPEUTICS INC03152W109COM1,600,000$15,424,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM250,000$14,203,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock672,559$14,151,000thousands by filing date
REPARE THERAPEUTICS INC760273102COM436,089$13,597,000thousands by filing date
FIBROGEN INC31572Q808COM500,000$13,315,000thousands by filing datecall
OCULAR THERAPEUTIX INC67576A100COM919,887$13,044,000thousands by filing date
INTERSECT ENT INC46071F103COM700,000$11,963,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK1,300,000$11,934,000thousands by filing date
BIOGEN INC COM09062X103Stock32,500$11,254,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock1,111,111$10,867,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock500,000$10,425,000thousands by filing date
ANAPTYSBIO INC032724106COM400,051$10,373,000thousands by filing date
OLEMA PHARMACEUTICALS INC68062P106COM329,086$9,208,000thousands by filing date
TRICIDA INC89610F101COM1,974,000$8,528,000thousands by filing date
Inflarx NvN44821101COM2,200,000$6,534,000thousands by filing date
RIGEL PHARMACEUTICALS INC766559603COMMON STOCK1,500,000$6,510,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK1,000,000$6,330,000thousands by filing date
AEGLEA BIOTHERAPEUTICS INC00773J103COM900,000$6,264,000thousands by filing date
VERVE THERAPEUTICS INC92539P101COM35,000$2,109,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-21-001868this filing2021-08-16acceptance time not in the bulk data set